Skip to main content
    N

    Neumora Therapeutics, Inc. (NMRA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.37
    -0.06 (-13.85%)

    Market Cap: $80.59M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Neumora Therapeutics, Inc. (NMRA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Neumora Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$236.93M, operating cash flow was -$206.44M and free cash flow was -$206.44M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$34.44M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $241.16M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Cost of revenue$0$0$0$0$1.55MN/AN/A
    Gross profit$0$0$0$0-$1.55MN/AN/A
    Research and development$181.06M$200.93M$206.62M$104.75M$212.78M$87.13M$0
    Operating income-$241.16M-$263.46M-$252.10M-$135.87M-$237.32M-$95.52MN/A
    Net income-$236.93M-$243.79M-$235.93M-$130.90M-$237.31M-$99.27MN/A
    EBITDAN/A-$262.91M-$251.60M-$134.87M-$236.77M-$95.41MN/A
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Gross profit$0$0$0N/A$0$0$0N/A$0$0$0-$166.00K
    Operating income-$33.41M-$42.19M-$52.86M-$58.48M-$57.70M-$54.04M-$70.94M-$62.92M-$76.65M-$63.82M-$60.07M-$114.00M
    Net income-$34.44M-$43.08M-$53.46M-$59.45M-$56.76M-$52.73M-$67.99M-$58.82M-$72.55M-$58.70M-$53.72M-$108.73M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $54.82M by $127.71M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$191.05M$316.97M$496.19M$426.23M$429.30M$197.95M$0
    Current assets$190.54M$314.06M$478.28M$387.95M$415.60M$193.84M$0
    Cash and equivalents$182.53M$142.15M$374.04M$240.94M$409.25M$191.98M$0
    Total liabilities$87.18M$29.91M$27.12M$29.40M$754.52M$292.33M$21.00K
    Short-term debt$284.00K$1.85M$3.38M$3.37M$1.06M$764.00KN/A
    Long-term debt$54.53M$0N/AN/AN/AN/AN/A
    Shareholder equity$103.87M$287.06M$469.08M-$446.85M-$325.22M-$94.38M-$21.00K
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$95.05M$125.25M$153.88M$191.05M$177.83M$223.82M$256.75M$316.97M$352.54M$404.47M$450.21M$496.19M
    Total liabilities$76.50M$80.73M$83.20M$87.18M$45.67M$40.95M$28.38M$29.91M$31.80M$23.21M$25.67M$27.12M
    Cash and equivalents$85.65M$116.83M$147.07M$182.53M$129.07M$124.52M$126.86M$142.15M$275.71M$150.68M$182.93M$374.04M
    Shareholder equity$18.55M$44.52M$70.68M$103.87M$132.16M$182.88M$228.36M$287.06M$320.74M$381.26M$424.54M$469.08M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$206.44M-$182.94M-$163.28M-$114.90M-$75.42M-$26.76M-$26.76M
    Capital expenditures$0$0$117.00K$511.00K$817.00K$1.30M$1.30M
    Free cash flow-$206.44M-$182.94M-$163.40M-$115.41M-$76.24M-$28.06M-$28.06M
    Investing cash flow$168.52M-$70.56M$64.39M-$168.01M-$817.00K-$11.24M-$11.24M
    Financing cash flow$77.09M$21.60M$231.94M$115.74M$293.51M$230.10M$230.10M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$33.44M-$39.53M-$46.40M-$47.95M-$46.63M-$52.40M-$59.45M-$50.34M-$33.48M-$56.16M-$42.95M-$51.44M
    Capital expendituresN/AN/A$0$16.00K$16.00K$0$0$0$775.00K$0$775.00K$44.00K
    Free cash flowN/AN/A-$46.40M-$47.97M-$46.65M-$52.40M-$59.45M-$50.34M-$34.26M-$56.16M-$43.73M-$51.49M
    Last 12 quarters

    Frequently Asked Questions About NMRA

    What is Neumora Therapeutics' annual revenue?

    Neumora Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Neumora Therapeutics profitable?

    No. Neumora Therapeutics reported net income of -$236.93M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does NMRA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$206.44M minus capital expenditures of $0 produced free cash flow of -$206.44M.

    How much debt does Neumora Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $54.53M, short-term debt of $284.00K and cash and equivalents of $182.53M.